Increased levels of LPA in the ascites of the ovarian cancer patients and a robust membrane-bound LPA-synthetic machinery quite adjacent to LPA-receptors in ovarian cancer cells raise the concentration of LPA in the tumor microenvironment to micromolar concentrations, which may not allow LPA-receptor antagonist to be used as an effective therapeutic agents. This evidence concerns the gene LPA and ovarian carcinoma.